127 related articles for article (PubMed ID: 34159488)
1. From ICI to ICU: Ipilimumab and Nivolumab-Induced Immune Checkpoint Inhibitor Colitis.
Zhou W; Frye J; Soroudi C; Triadafilopoulos G; Berry R
Dig Dis Sci; 2022 Mar; 67(3):800-803. PubMed ID: 34159488
[No Abstract] [Full Text] [Related]
2. Immune checkpoint inhibitor-induced diarrhea: Clinicopathological study of 11 patients.
Yanai S; Nakamura S; Kawasaki K; Toya Y; Akasaka R; Oizumi T; Ishida K; Sugai T; Matsumoto T
Dig Endosc; 2020 May; 32(4):616-620. PubMed ID: 31595568
[TBL] [Abstract][Full Text] [Related]
3. Medication-specific variations in morphological patterns of injury in immune check-point inhibitor-associated colitis.
Isidro RA; Ruan AB; Gannarapu S; Raj D; Rahma O; Grover S; Srivastava A
Histopathology; 2021 Mar; 78(4):532-541. PubMed ID: 32931028
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitor induced colitis: A nationwide population-based study.
Farha N; Alkhayyat M; Lindsey A; Mansoor E; Saleh MA
Clin Res Hepatol Gastroenterol; 2022 Jan; 46(1):101778. PubMed ID: 34332139
[TBL] [Abstract][Full Text] [Related]
5. Long-term immune-related adverse events after discontinuation of immunotherapy.
Horisberger K; Portenkirchner C; Rickenbacher A; Biedermann L; Gubler C; Turina M
Immunotherapy; 2021 Jun; 13(9):735-740. PubMed ID: 33882697
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Outcome of Tofacitinib in Immune checkpoint Inhibitor Colitis.
Bishu S; Melia J; Sharfman W; Lao CD; Fecher LA; Higgins PDR
Gastroenterology; 2021 Feb; 160(3):932-934.e3. PubMed ID: 33096100
[No Abstract] [Full Text] [Related]
7. Toxic epidermal necrolysis occurring with immune checkpoint inhibitors.
Gopee NH; Gourley AM; Oliphant TJ; Hampton PJ
Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941713
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibitor-Induced Ptosis in a Patient With Prostate Cancer.
Williams KJ; Allen RC
J Neuroophthalmol; 2021 Mar; 41(1):e71-e72. PubMed ID: 32235233
[No Abstract] [Full Text] [Related]
9. Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation.
Valenti-Azcarate R; Esparragosa Vazquez I; Toledano Illan C; Idoate Gastearena MA; Gállego Pérez-Larraya J
Neuromuscul Disord; 2020 Jan; 30(1):67-69. PubMed ID: 31839404
[TBL] [Abstract][Full Text] [Related]
10. Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report.
Yaura K; Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
Tohoku J Exp Med; 2021 Aug; 254(4):253-256. PubMed ID: 34373422
[TBL] [Abstract][Full Text] [Related]
11. Magnetic resonance imaging criteria of immune checkpoint inhibitor-induced hypophysitis.
Nada A; Bhat R; Cousins J
Curr Probl Cancer; 2021 Feb; 45(1):100644. PubMed ID: 32888700
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitor-induced granulomatosis with polyangiitis.
Hung W; Cusnir I; Habib S; Smylie M; Solez K; Yacyshyn E
Rheumatology (Oxford); 2021 Jun; 60(6):e190-e191. PubMed ID: 33367837
[No Abstract] [Full Text] [Related]
13. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
Wong JSL; Kwok GGW; Tang V; Li BCW; Leung R; Chiu J; Ma KW; She WH; Tsang J; Lo CM; Cheung TT; Yau T
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563773
[TBL] [Abstract][Full Text] [Related]
14. Immune-related pancytopenia caused by nivolumab and ipilimumab combination therapy for unresectable melanoma of unknown primary.
Uehara J; Yoshino K; Sugiyama E; Ohkuma K; Oaku S; Yamashita C; Hiura A; Fujisawa Y
J Dermatol; 2020 Jun; 47(6):e237-e239. PubMed ID: 32270507
[No Abstract] [Full Text] [Related]
15. First case of hemophagocytic lymphohistiocytosis secondary to cabozantinib with checkpoint inhibitors.
Azari AE; Stratton R; Singh A
Rheumatology (Oxford); 2021 May; 60(5):e167-e168. PubMed ID: 33280022
[No Abstract] [Full Text] [Related]
16. Serious disseminated intravascular coagulation associated with combination therapy of nivolumab and ipilimumab in advanced melanoma.
Kuriyama H; Fukushima S; Nakahara S; Kanemaru H; Miyashita A; Aoi J; Tomita Y; Kawasaki T; Nosaka K; Ihn H
J Dermatol; 2020 Jun; 47(6):e235-e237. PubMed ID: 32275077
[No Abstract] [Full Text] [Related]
17. Severe enterocolitis secondary to ipilimumab and nivolumab with an excellent response to a single dose of infliximab.
Luque Carmona AM; Ontanilla-Clavijo G; Leo Carnerero E
Rev Esp Enferm Dig; 2020 Nov; 112(11):889-890. PubMed ID: 33054275
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitor induced large vessel vasculitis.
Henderson D; Eslamian G; Poon D; Crabb S; Jones R; Sankey P; Kularatne B; Linch M; Josephs D
BMJ Case Rep; 2020 May; 13(5):. PubMed ID: 32430351
[TBL] [Abstract][Full Text] [Related]
19. Immune-Mediated Colitis due to Concurrent Ipilimumab and Nivolumab Therapy Treated With Infliximab.
Karanfilian B; Dalal I; Bhurwal A; Patel AV
Am J Ther; 2020; 27(4):e415-e417. PubMed ID: 32355083
[No Abstract] [Full Text] [Related]
20. Encephalitis Induced by Immune Checkpoint Inhibitors: A Systematic Review.
Velasco R; Villagrán M; Jové M; Simó M; Vilariño N; Alemany M; Palmero R; Martínez-Villacampa MM; Nadal E; Bruna J
JAMA Neurol; 2021 Jul; 78(7):864-873. PubMed ID: 33720308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
